Study of EB-001 in Facial Scar Reduction

Mohs Surgery Clinical Trial

Official title: A Phase 2 Study to Evaluate Safety and Efficacy of EB-001 Injections in Facial Scar Reduction After Undergoing Mohs Surgery

Status Completed

Clinical Trial Summary

This study will evaluate the safety and efficacy of EB-001 in improving wound healing and reducing scar formation in patients undergoing Mohs surgery for skin lesions in the forehead area following a single treatment of EB-001 when injected into the muscles underlying the incision area.

Clinical Trial Description

This study will evaluate the safety and efficacy of EB-001 in improving wound healing and reducing scar formation in patients undergoing Mohs surgery for skin lesions in the forehead area following a single treatment of EB-001 when injected into the muscles underlying the incision area.

The safety objective is to determine the safety and tolerability of single treatment of EB-001 when injected into facial muscles underlying a surgical wound during Mohs surgery.

The efficacy objective is to evaluate the efficacy of a single treatment of EB-001 when injected into the facial muscles (frontalis) underlying the surgical wound in improving wound healing, and reducing scar formation. ;

Related Conditions & MeSH terms

• Mohs Surgery

• NCT number: NCT03346902
• Study type: Interventional
• Source: Bonti, Inc.
• Status: Completed
• Phase: Phase 2
• Start date: February 6, 2018
• Completion date: October 8, 2018